Alembic Pharmaceuticals rises on getting final approval from USFDA for Metolazone tablets

Alembic Pharmaceuticals today announced that it has received approval from United States Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Metolazone tablets USP 2.5 mg, 5 mg, and 10 mg.

Reacting to this, the stock of Alembic Pharmaceuticals jumped 2.27 per cent and made an intraday high of Rs 1,016 per share.

Metolazone tablets USP 2.5 mg, 5 mg, and 10 mg are therapeutically equivalent to Zaroxolyn tablets 2.5 mg, 5 mg, and 10 mg of Lannett Company, Inc.

Metolazone tablets are indicated for the treatment of Edema, accompanying congestive heart failure, and Edema accompanying renal diseases, including nephrotic syndrome and states of diminished renal function. These are also used for the treatment of hypertension.

Presently, Alembic Pharma has 137 ANDA approvals from USFDA, out of which, 118 are final approvals and 19 tentative approvals.

Alembic manufactures & markets generic pharmaceutical products all over the world. The company's research & manufacturing facilities are approved by regulatory authorities of many developed countries including USFDA. It is one of the leading branded generics in India.

At 11.52 am today, the share of Alembic Pharmaceuticals was trading at Rs 1,007.15 per share on BSE, up by 1.38 per cent.